Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
11 avr. 2024 07h55 HE
|
Enliven Therapeutics, Inc.
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial...
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
09 avr. 2024 16h05 HE
|
Enliven Therapeutics, Inc.
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
28 mars 2024 16h05 HE
|
Enliven Therapeutics, Inc.
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
19 mars 2024 08h30 HE
|
Enliven Therapeutics, Inc.
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026...
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
14 mars 2024 16h05 HE
|
Enliven Therapeutics, Inc.
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in...
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
27 févr. 2024 16h05 HE
|
Enliven Therapeutics, Inc.
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation...
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
09 nov. 2023 16h05 HE
|
Enliven Therapeutics, Inc.
Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable...
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
10 août 2023 16h05 HE
|
Enliven Therapeutics, Inc.
Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024 Strong balance...
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
31 mai 2023 16h55 HE
|
Enliven Therapeutics, Inc.
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of...
Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
11 mai 2023 16h05 HE
|
Enliven Therapeutics, Inc.
Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN” Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell...